Aug 2026· Journal of Agricultural and Food Chemistry· Vol 74 34, pp.
27286-27297
· 0 citations· 32 references
Medicine
TL;DR
Compound 6o represents a promising lead for novel demethylation inhibitor fungicides for crop protection and exhibited good biosafety toward apple and rice seedlings.
Abstract
Sterol 14α-demethylase (CYP51) and squalene epoxidase (SE) are rate-limiting enzymes in ergosterol biosynthesis, and their inhibition markedly retards fungal growth. A series of novel (1,2,4-triazol-1-yl)propan-2-ol derivatives were designed based on reported CYP51/SE inhibitor scaffolds. Bioassays demonstrated that compound 6o exhibited broad-spectrum antifungal activity, with EC50 values of 0.25, 0.38, and 0.49 mg/L against Valsa mali, Rhizoctonia solani, and Curvularia lunata, respectively. At 100 mg/L, compound 6o achieved 84.6% in vivo control efficacy against V. mali, comparable to difenoconazole (88.1%). Further studies revealed that compound 6o blocked ergosterol synthesis, damaged cell membrane integrity, elevated membrane permeability, and triggered intracellular ROS accumulation in V. mali. Enzyme activity tests, molecular docking, and qRT-PCR analyses suggested that compound 6o acts as a dual inhibitor of CYP51 and SE. Moreover, compound 6o exhibited good biosafety toward apple and rice seedlings. Collectively, compound 6o represents a promising lead for novel demethylation inhibitor fungicides for crop protection.
Mechanistic studies revealed that Q8 disrupted cell membrane integrity and inhibited succinate dehydrogenase (SDH) activity, with computational simulations suggesting a higher binding affinity for SDH than fluopyram.
Qing-Xue Hu, Xiao-Ting Geng, Fang Tian et al.· Journal of Agricultural and...· 0 citations
Findings identify compound 9b as a promising lead α-glucosidase inhibitor with potent in vitro and in vivo antihyperglycemic activity, warranting further investigation for the treatment of type 2 diabetes.
Elika Salehi Ghalehsefid, Mohammad Halimi, Hassan Mohammadi et al.· European journal of medicina...· 0 citations
Experimental findings identify compounds 8c and 9e as promising lead scaffolds for the development of next-generation inhibitors of urease and α-glucosidase.
Mohammad A. Alrofaidi· Journal of Visualized Experi...· 0 citations
Kinetic enzyme assays revealed that compound 9f acts as a competitive inhibitor of α-glucosidase, competing with the natural substrate for binding to the active site, with a Ki value of 100 nM, and pharmacokinetic predictions showed that compound 9f exhibits a bioavailability radar and drug-likeness profile similar to...
Shahab Kermaninia, M. Sayahi, Mohammad Halimi et al.· RSC Advances· 0 citations
(R)-A17, a novel, highly selective PARP1 inhibitor featuring a unique tricyclic scaffold, is developed and established as a promising candidate and the design strategy for the next-generation PARP1-targeted therapy is validated.
Zhongning Guo, Rongrong Sun, Lin-Yu Yang et al.· Journal of Medicinal Chemist...· 0 citations
Results suggest that the N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold is a useful template for designing selective BCR-ABL1-directed anticancer agents, with compound 9c as an encouraging lead for further optimisation and mechanistic studies.
Pradeep B. Bhise, Sandeep B. Bhise, Somnath Dasgupta et al.· RSC Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.